Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results.

Home Research Research Publication Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results. Ophthalmology. 2018 Nov 28. pii: S0161-6420(18)32316-9. doi: 10.1016/j.ophtha.2018.11.025. [Epub ahead of print] PMID: 30502372

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

(08) 9381 0777

carecentre@lei.org.au

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results.

Need any help?

Request an appointment